Boston Scientific Forgoes Cost Cuts, Predicting Stent/ICD Market Recovery

Boston Scientific will maintain current cost structures in its drug-eluting stent and cardiac rhythm management businesses in the near term, anticipating both markets will soon recover from a 2006 slump